PI60 Stock Overview
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pieris Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.06 |
| 52 Week High | US$68.88 |
| 52 Week Low | US$9.98 |
| Beta | 0.50 |
| 1 Month Change | -17.67% |
| 3 Month Change | -19.97% |
| 1 Year Change | -82.38% |
| 3 Year Change | -92.27% |
| 5 Year Change | -95.49% |
| Change since IPO | -95.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| PI60 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -0.5% |
| 1Y | -82.4% | -21.0% | 2.5% |
Return vs Industry: PI60 underperformed the German Biotechs industry which returned -21% over the past year.
Return vs Market: PI60 underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| PI60 volatility | |
|---|---|
| PI60 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PI60's share price has been volatile over the past 3 months.
Volatility Over Time: PI60's weekly volatility has decreased from 26% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 48 | Steve Yoder | www.pieris.com |
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Pieris Pharmaceuticals, Inc. Fundamentals Summary
| PI60 fundamental statistics | |
|---|---|
| Market cap | €12.94m |
| Earnings (TTM) | -€22.85m |
| Revenue (TTM) | €39.86m |
0.3x
P/S Ratio-0.6x
P/E RatioIs PI60 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PI60 income statement (TTM) | |
|---|---|
| Revenue | US$42.81m |
| Cost of Revenue | US$41.80m |
| Gross Profit | US$1.01m |
| Other Expenses | US$25.55m |
| Earnings | -US$24.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -19.85 |
| Gross Margin | 2.36% |
| Net Profit Margin | -57.33% |
| Debt/Equity Ratio | 0% |
How did PI60 perform over the long term?
See historical performance and comparison